Based on rocplot.plot, among those patients who received neoadjuvant taxane (AUC = 0.59, p = 3.1e − 7), anthracycline (AUC = 0.60, p = 1.1e − 11), ixabepilone (AUC = 0.61, p = 0.04), and FAC (AUC = 0.6, p = 6.6e − 3), the PTPRT expression level was higher in no-responders than those in responders....PTPRT could predict chemotherapy effectiveness and prognosis for breast cancer patients.